section name header

Basic Information

AUTHORS: Bethany K Sederdahl, MPH, MD, and Anthony Sciscione, DO

Definition

Genital infection with Chlamydia trachomatis (CT) is the most prevalent sexually transmitted disease in the U.S. In women, chlamydia infection can result in cervicitis, acute urethral syndrome, endometritis, and pelvic inflammatory disease. These infections can, in turn, lead to ectopic pregnancy, infertility, and chronic pelvic pain (see “Pelvic Inflammatory Disease”). In men, CT infection may cause mucopurulent discharge, urethritis, epididymitis, and prostatitis. Newborns born via an infected birth canal are at risk for conjunctivitis and pneumonia. A majority of the men and women affected with CT are asymptomatic. Thus, screening tests play a very important role in detection of this infection to initiate treatment, impede disease sequelae, and prevent further transmissions.1,2

ICD-10CM CODES
A56.2Chlamydial infection of genitourinary tract, unspecified
A56Other sexually transmitted chlamydial diseases
A56.0Chlamydial infection of lower genitourinary tract
A56.00Chlamydial infection of lower genitourinary tract, unspecified
A56.01Chlamydial cystitis and urethritis
A56.02Chlamydia vulvovaginitis
A56.09Other chlamydial infection of lower genitourinary tract
A56.1Chlamydial infection of pelviperitoneum and other genitourinary organs
A56.19Other chlamydial genitourinary infection
A56.2Chlamydial infection of genitourinary tract, unspecified
A56.3Chlamydial infection of anus and rectum
A56.4Chlamydial infection of pharynx
A56.8Sexually transmitted chlamydial infection of other sites
Epidemiology & Demographics

  • C. trachomatis is the most commonly reported sexually transmitted disease in the U.S., with more than 1.5 million cases reported to the Centers for Disease Control and Prevention (CDC) in 2020. This represents a decreased in reported cases with 1.8 million cases reported in 2019. Rather than a decrease in disease, this is believed to represent lack of access to outpatient testing and treatment during the COVID-19 pandemic.2
  • Regardless, because many cases of CT infection are asymptomatic and likely remain undiagnosed.
  • Age is a strong predictor for risk of CT infection. Individuals less than 25 yr old are the largest age group affected by C. trachomatis; 61% of reported chlamydia infections were among individuals ages 15 to 24 yr.2
  • Chlamydia conjunctivitis occurs in 18% to 44% of infants, and chlamydial pneumonia occurs in 3% to 16% of infants who are delivered by mothers with untreated CT infection at the time of delivery.3
  • Pelvic inflammatory disease develops in 10% to 15% of women with untreated CT infections.3
  • Untreated CT increases a person’s risk of acquiring HIV.3
  • In men, 15% to 55% of nongonococcal urethritis cases are caused by C. trachomatis.
  • Anorectal chlamydia infection can occur in partners who engage in anal sex and is more common among men who have sex with men.3
  • Table E1 summarizes clinical characteristics of common C. trachomatis infections.

TABLE E1 Clinical Characteristics of Common Chlamydia trachomatis Infections

InfectionSymptoms and SignsPresumptive DiagnosisDefinitive DiagnosisTreatment
MenNongonococcal urethritisUrethral discharge, dysuriaUrethral leukocytosis; no gonococci seenUrine or urethral NAATDoxycycline, 100 mg PO bid, for 7 days
EpididymitisUnilateral epididymal tenderness, swelling; pain; fever, presence of NGUUrine or urethral NAATUrethral leukocytosis; pyuria on urinalysisSTI likely: Ceftriaxone 500 mg (1 g for individuals weighing >150 kg) IM plus doxycycline, 100 mg PO bid, for 10 days
If enteric organisms are suspected:
Ceftriaxone, 500 mg (1 g for individuals weighing >150 kg) IM, plus levofloxacin, 500 mg bid for 10 days
Proctitis (non-LGV)Rectal pain, discharge and bleeding; history of receptive anal intercourse1 PMN/OIF on rectal Gram stain; no gonococci seenUrine or urethral NAAT; rectal culture or NAATCeftriaxone, 500 mg (1 g for individuals weighing >150 kg) IM, plus Doxycycline, 100 mg PO bid, for 7 days
Lymphogranuloma venereum proctitisPainful, tender inguinal lymphadenopathy, fever“Groove sign”Urine, urethral, lymph node or rectal NAAT; rectal or lymph node culture; LGV-specific testing if availableDoxycycline, 100 mg PO bid, for 21 days
WomenCervicitisMucopurulent cervical discharge; ectopy, easily induced bleeding20 PMN/OIF on cervical Gram stainUrine or cervical NAATDoxycycline, 100 mg PO bid, for 7 days
UrethritisDysuria, frequency; no hematuriaPyuria on UA; negative urine Gram stain and cultureUrine, cervical, or urethral NAATDoxycycline, 100 mg PO bid for 7 days
Pelvic inflammatory diseaseLower abdominal pain, adnexal pain, cervical motion tendernessEvidence of mucopurulent cervicitisUrine or cervical NAATOutpatient: Ceftriaxone 500 mg IM as a single dose, plus doxycycline 100 mg PO bid for 14 days, with metronidazole, 500 mg PO bid for 14 days
AdultsConjunctivitisOcular pain, redness, discharge; simultaneous genital infectionGram stain of conjunctival swab negative for bacterial pathogens; PMNs on smearDFA or NAAT on conjunctival swabDoxycycline, 100 mg PO bid for 7 days
NewbornsConjunctivitisOcular pain, redness, discharge; simultaneous genital infectionGram stain of conjunctival swab negative for bacterial pathogens; PMNs on smearDFA or NAAT on conjunctival swab; vagina, rectum, pharynx also often positiveErythromycin base 50 mg/kg/day, PO divided into four doses daily for 14 days; evaluate and treat parents as well
PneumoniaStaccato cough, tachypnea, hyperinflationDiffuse interstitial infiltrate, eosinophiliaNasopharyngeal NAATs or culture; MIF serology (IgM)Erythromycin base or ethylsuccinate 50 mg/kg/day, PO divided into four doses daily for 14 days; evaluate and treat parents as well

bid, Twice daily; DFA, Direct fluorescent antibody; IgM, immunoglobulin M; IM, intramuscular; LGV, lymphogranuloma venereum; MIF, microimmunofluorescence; MSM, men who have sex with men; NAAT, nucleic acid amplification test; NGU, nongonococcal urethritis; OIF, oil immersion field; PMN, polymorphonuclear neutrophil; PO, by mouth; STI, sexually transmitted infection; UA, urinalysis.

From Bennett JE et al: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, ed 8, Philadelphia, 2015, Saunders; updated with new treatment guidelines from the Centers for Disease Control and Prevention.

Physical Findings & Clinical Presentation

  • Chlamydial infections are commonly asymptomatic. Clinical manifestations in symptomatic women affected with C. trachomatis may include vaginal discharge or irregular vaginal bleeding. Purulent discharge or cervicitis may be visualized on speculum examination. Easily induced endocervical bleeding can be noted on examination and is caused by inflammation of endocervical columnar epithelium. Untreated infection can ascend the reproductive tract, causing pelvic inflammatory disease. Clinical signs of pelvic inflammatory disease are cervical, uterine, or adnexal tenderness on examination. Complications of pelvic disease are ectopic pregnancy, infertility, and chronic pelvic pain.
  • Symptoms in men may include dysuria or a mucopurulent penile discharge. A complication that can arise from CT infection in men is epididymitis, which manifests as unilateral testicular pain, hydrocele, or swelling of the epididymis. An untreated CT infection can also cause prostatitis in men. Prostatitis may present as urinary dysfunction, pain with ejaculation, and pelvic pain.
  • Chlamydial conjunctivitis can be experienced by both men and women and is the result of conjunctiva exposed to infected genital secretions. CT infection can also cause proctitis or infection of the rectum in men and women. This usually presents with rectal pain, discharge, or bleeding. CT infection of the throat is usually asymptomatic in both men and women and not a usual cause of pharyngitis. Less frequent manifestations of CT infection may include perihepatitis (Fitz-Hugh-Curtis syndrome) or reactive arthritis (Reiter syndrome).
Etiology

  • C. trachomatis consists of 15 serotypes
  • Obligate, intracellular bacteria

Diagnosis

Differential Diagnosis

Differential diagnosis depends on presenting symptoms. Some of the common differentials are listed in the following

  • Candidiasis
  • Conjunctivitis
  • Ectopic pregnancy
  • Endometriosis
  • Gonorrhea
  • Mycoplasma infection
  • Pelvic inflammatory disease
  • Trichomonas
  • Urethritis
  • Urinary tract infection
Workup

Individuals with signs and symptoms mentioned previously should be screened for CT infection. Because majority of CT infections are asymptomatic, routine screening should be offered to individuals at risk for CT infection. In women, screening reduces the rate of PID. Annual screening is thus recommended for all sexually active women less than 25 yr of age and women at any age at risk for sexually transmitted infections. Risk factors include a new sexual partner, more than one sexual partner, individuals not in a mutually monogamous relationship, a previous or concurrent sexually transmitted disease, or working in the sex industry for profit. Screening interval is determined by any new risk for exposure since the last negative screening. The CDC recommends CT screening for all pregnant women under the age of 25 and for any pregnant woman over the age of 25 who is at increased risk for acquiring CT at their initial prenatal care visit. These same pregnant women should be screened again during the third trimester. At a minimum, annual screening is also recommended for men who have sex with men and persons with HIV.1,3

Laboratory Tests

  • Nucleic acid amplification tests (NAATs) are the gold standard for diagnosis because of their high sensitivity and specificity for the detection of CT infection. The FDA has approved these tests for male and female urine collection and for provider-collected endocervical, vaginal, and male urethral specimens.1,3
  • Rectal and pharyngeal collection site specimens may be taken from individuals who engage in receptive anal and oral intercourse, but these collection sites are not FDA approved.
  • For best results, urine collection should be completed with a first-void urine sample.
  • Self-collected vaginal swab samples for women have the same sensitivity and specificity as provider-collected samples.
  • The same specimen can be used to test for chlamydia and gonorrhea.
  • Sexual partners of a person testing positive for CT infection should be treated if they had sexual contact with that individual within 60 days before onset of symptoms or CT diagnosis.
  • Microscopy should not be used for chlamydia diagnosis; however, >10 white blood cells per high-power field with a mucopurulent discharge can be a presumptive diagnosis.

Treatment

Acute General Rx
Adolescents & Adults

Nongonococcal urethritis, urethritis, cervicitis, conjunctivitis (except for lymphogranuloma venereum):

  • Doxycycline 100 mg PO bid for 7 days
Infection in Pregnancy

  • Azithromycin 1 g PO single-dose therapy
Alternative Regimens

  • Azithromycin 1 g PO × single-dose therapy or
  • Levofloxacin 500 mg/day PO for 7 days
  • Alternative regimen in pregnancy: Amoxicillin 500 mg PO tid for 7 days

NOTE: Azithromycin (Pregnancy Risk Category B) is generally considered safe and effective during pregnancy and with lactation. Doxycycline is contraindicated in pregnancy.

Follow-Up

  • Observed single-dose therapy should be offered to individuals for whom compliance is a concern.
  • To minimize disease transmission to partners, affected persons should be advised to refrain from sexual intercourse for 7 days after single-dose therapy, until completion of 7-day therapy, or until resolution of symptoms.
  • To prevent reinfection, affected individuals should refrain from sexual intercourse until all of their partners have been treated.
  • Re-collection by NAAT method in <4 wk from treatment can yield a false-positive result due to the sensitivity of this testing method.
  • Both men and women treated for chlamydia should be retested at approximately 3 mo after treatment to screen for reinfection. If patients do not return to clinical settings within 3 mo, rescreen the patient at the next presentation for clinical care.
  • Pregnant women with C. trachomatis infection should have a test of cure 4 wk after treatment and should then be retested within 3 mo.

Refer partners for evaluation and treatment.

Recurrent & Persistent Urethritis

Retreat noncompliant patients with the above regimens. If patient was initially compliant, recommended regimens include metronidazole 2 g PO in single dose plus erythromycin base 500 mg PO qid for 7 days or erythromycin ethylsuccinate 800 mg PO qid for 7 days.

Rectal Chlamydia

A 7-day course of doxycycline (100 mg twice daily for 7 days) is superior to single-dose infection among men who have sex with men.1

Referral

Refer to infectious disease specialist if persistent infection or gynecologist if salpingitis is suspected.

Related Content

Cervicitis (Related Key Topic)

Urethritis, Gonococcal (Related Key Topic)

Gonorrhea (Related Key Topic)

Urethritis, Nongonococcal (Related Key Topic)

Pelvic Inflammatory Disease (Related Key Topic)

Related Content

    1. Workowski K.A. : Sexually transmitted infections treatment guidelines, 2021MMWR Recomm Rep. ;70(No. RR-4):1-187, 2021.
    2. Centers for Disease Control and Prevention : Sexually transmitted disease surveillance , 2020.https://www.cdc.gov/std/statistics/2020/overview.htm#Chlamydia
    3. Centers for Disease Control and Prevention. Chlamydia: CDC detailed fact sheet, https://www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm.
    4. U.S. Preventive Services Task Force: Chlamydia and gonorrhea: screening, https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/chlamydia-and-gonorrhea-screening.